Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 4/20 | 0.31 |
| ▸ | HTR2A | P28223 | 3/20 | 0.31 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.31 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20030625 | 0.91 | SRD5A1 (0.32) | KDM1AKMT2AHTR2CHTR2AAKR1B1 | |
| SCHEMBL21119087 | 0.87 | AKR1B1 (0.32) | KDM1AHTR2CHTR2AAKR1B1HTR2B | |
| SCHEMBL20031068 | 0.82 | TMEM97 (0.38) | KDM1ASLC6A4SLC6A3 | |
| SCHEMBL21119417 | 0.78 | KDM1A (0.42) | KDM1A | |
| SCHEMBL18022626 | 0.77 | SRD5A1 (0.36) | KDM1AKMT2AHTR2CHTR2ASLC6A4 | |
| SCHEMBL20031030 | 0.75 | HTR2A (0.31) | HTR2A | |
| SCHEMBL24080197 | 0.71 | SCN4A (0.36) | HTR2CSLC6A4SLC6A3HTR2B | |
| SCHEMBL24080177 | 0.71 | SCN4A (0.36) | HTR2CSLC6A4SLC6A3HTR2B | |
| SCHEMBL24080186 | 0.70 | EED (0.34) | — | |
| SCHEMBL17980202 | 0.68 | SLC6A4 (0.33) | KDM1AHTR2CHTR2ASLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11192885-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-10336732-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180093974-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2018-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192885-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | CNR1, HCRTR1, CNR2 | KDM1A 1189/4885KMT2A 676/4885HTR2C 55/4885 |
| US-20180093974-A1 | 1-HETEROCYCLYL ISOCHROMANYL COMPOUNDS AND ANALOGS FOR TREATING CNS DISORDERS | CNR1, HCRTR1, CNR2 | KDM1A 1189/4885KMT2A 676/4885HTR2C 55/4885 |
| US-10336732-B2 | 1-heterocyclyl isochromanyl compounds and analogs for treating CNS disorders | CNR1, HCRTR1, CNR2 | KDM1A 1189/4885KMT2A 676/4885HTR2C 55/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.